Protease inhibitor-induced diabetic complications : incidence, management and prevention.
Protease inhibitors (PIs) have become a crucial element in the treatment of patients infected with HIV. However, the widespread use of PI therapy has also been associated with a number of metabolic adverse effects, including fat redistribution and hyperglycaemia. The objective of this review is a discussion of the incidence, pathophysiology, management and prevention of PI-associated hyperglycaemia. Initial case reports have been followed by large cross-sectional and cohort studies, which demonstrate that the incidence of PI-induced impaired glucose tolerance, as well as frank diabetes mellitus, is significant and demands attention. Investigations into the pathophysiology behind PI-associated hyperglycaemia have identified an underlying problem of insulin resistance that is presumably caused by both direct PI-induced mechanisms and lipotoxicity. Given this, clinical trials have explored the use of various classes of oral hypoglycaemic agents in the management of PI-induced diabetic complications, and the use of insulin therapy must be considered as well. Newer PI agents are also under development, with the hope of reducing metabolic adverse effects. In the meantime, prevention, in the form of dietary modification, regular physical activity and periodic screening for impaired glucose tolerance, must receive heightened attention in the care plan of patients receiving long-term PI therapy.
Lien
Lillian F
LF
Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. lien0002@mc.duke.edu
Feinglos
Mark N
MN
D048909:Diabetes Complications / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control*; D004358:Drug Therapy; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D011480:Protease Inhibitors
Clin Infect Dis. 2002 Jan 15;34(2):248-59
11740715
J Clin Endocrinol Metab. 2000 Oct;85(10):3544-50
11061499
Clin Infect Dis. 2002 Aug 15;35(4):475-81
12145733
J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75
12439201
Clin Infect Dis. 2001 Sep 1;33(5):710-7
11486294
Lancet. 1995 Jul 8;346(8967):120-1
7603193
AIDS. 1998 May 7;12(7):F51-8
9619798
J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):35-43
10708054
AIDS Patient Care STDS. 2002 Dec;16(12):585-97
12542932
AIDS. 2002 Jul 5;16(10):1341-9
12131210
Diabet Med. 1998 Jul;15(7):539-53
9686693
JAMA. 2001 Oct 24-31;286(16):1945-8
11667913
AIDS. 1999 Jul 9;13(10):F63-70
10416516
Ann Pharmacother. 2004 Oct;38(10):1664-74
15353575
Diabetes. 2002 Nov;51(11):3163-9
12401706
Diabetes. 2002 Apr;51(4):937-42
11916910
AIDS. 1998 Jul 30;12(11):1399-400
9708427
Clin Infect Dis. 2002 May 15;34(10):1396-405
11981737
AIDS. 2000 May 5;14(7):903-5
10839604
J Biol Chem. 2000 Jul 7;275(27):20251-4
10806189
J Acquir Immune Defic Syndr. 1999 Jul 1;21(3):209-16
10421244
N Engl J Med. 2003 Sep 11;349(11):1036-46
12968087
AIDS. 1999 May 7;13(7):805-10
10357379
AIDS. 2002 Mar 29;16(5):F1-8
11964551
J Clin Endocrinol Metab. 2000 Jan;85(1):35-41
10634360
Clin Endocrinol (Oxf). 2000 Feb;52(2):241-3
10671953
Ann Pharmacother. 2000 May;34(5):580-4
10852083
J Infect Dis. 2001 Nov 1;184(9):1197-201
11598845
Control Clin Trials. 2001 Apr;22(2):142-59
11306153
AIDS. 1999 Oct 1;13(14):1987-9
10513665
Arch Intern Med. 2002 Dec 9-23;162(22):2621-8
12456235
JAMA. 2000 Jul 26;284(4):472-7
10904511
J Intern Med. 2002 Dec;252(6):570-4
12472919
AIDS Alert. 2003 Jan;18(1):6
12541993
Clin Infect Dis. 2000 Dec;31(6):1467-75
11096014
J Clin Endocrinol Metab. 2003 May;88(5):1961-76
12727939
Arch Med Res. 2000 Jan-Feb;31(1):81-4
10767485
J Clin Endocrinol Metab. 1999 Jun;84(6):1932-7
10372689
Diabetes Care. 1997 Jul;20(7):1183-97
9203460
Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E274-80
12388139
Lancet. 1999 Jun 19;353(9170):2093-9
10382692
Antivir Ther. 2003 Jun;8(3):199-207
12924536
AIDS. 2003 May 23;17(8):1179-93
12819520
Clin Infect Dis. 2002 Mar 1;34(5):716-7
11823959
AIDS. 2001 Apr 13;15(6):717-23
11371686
Ann Intern Med. 1997 Nov 15;127(10):947
9382374
Arch Intern Med. 2000 Jul 10;160(13):2050-6
10888979
Ann Pharmacother. 2001 Jul-Aug;35(7-8):877-80
11485138
Ann Intern Med. 2004 May 18;140(10):786-94
15148065
J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):399-401
11707680
AIDS. 1999 May 28;13(8):1000-2
10371188
Lancet. 2004 Feb 7;363(9407):429-38
14962523
Lancet. 1997 Sep 6;350(9079):713-4
9291911
Diabetes. 2003 Apr;52(4):918-25
12663461
Ann Intern Med. 1997 Nov 15;127(10):948
9382376
Ann Intern Med. 1999 Aug 17;131(4):281-303
10454950
J Clin Endocrinol Metab. 2001 Feb;86(2):939-43
11158071
CMAJ. 1999 Jul 27;161(2):161-4
10439826
Metabolism. 1997 Dec;46(12 Suppl 1):35-9
9439557
AIDS. 2003 May 2;17(7):987-99
12700448
Res Exp Med (Berl). 2000 Apr;199(5):253-62
10815754
Diabetologia. 1985 Jul;28(7):412-9
3899825
J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):163-70
12394794